The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | PET-boost study in NSCLC
Jose Belderbos, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the local failure (LF) and regional failure (RF) results from the Phase II PET-Boost trial (NCT01024829) in patients with non-small cell lung cancer (NSCLC). In this trial NSCLC patients were treated with hypofractioned dose escalation to either the primary tumor as a whole (arm A) or the high FDG-uptake region inside the primary tumor (arm B). In total, 107 patients were randomized in the trial and concurrent/sequential/no chemotherapy was allowed. Excellent local control rates were observed in both treatment arms. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
